Home LiteratureArticle Details
PMID: 26365985 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof.

Oral oncology ·Vol. 51 ·No. 11 ·2015-11-00 ·Pages 1004-1010

Chen TC, Wu CT, Wang CP, Hsu WL, Yang TL, Lou PJ, Ko JY, Chang YL

Abstract

The treatment strategies for advanced oral squamous cell carcinoma (OSCC), especially with necrotic changes, are not effective. The programmed death ligand 1 (PD-L1) immune escape may be one of the underlying sources of resistance. Furthermore, anti-PD-L1 directed immunotherapy may be another choice for adjuvant therapy. Therefore, the expression of PD-L1 in advanced OSCC with necrotic changes is very important. A total of 218 eligible patients with advanced stage (stage III/IV) OSCC and neck metastasis were enrolled. The presence of necrosis was reviewed by pretreatment magnetic resonance imaging. Paired paraffin-embedded primary tumor and metastatic lymph nodes (LN) sections were stained with antibodies against hypoxia-inducible factor-1α (HIF-1α) and PD-L1. Moderate-to strong HIF-1α nuclear staining in >10% and cell surface PD-L1 expression in >5% of OSCC cells were recorded as a positive result. For advanced OSCC with necrotic changes, there was substantial agreement in primary tumor (kappa value 0.54) and almost perfect agreement in metastatic LN (kappa value 0.86) between HIF-1α and PD-L1 expression. The patients with both necrosis and positive PD-L1 expression in OSCC surrounding necrosis had worse disease control and survival outcomes. After multivariate analysis, metastatic LN necrosis and positive PD-L1 expression were found to be significant independent adverse factors. Advanced OSCC patients with both necrosis and positive PD-L1 expression in OSCC surrounding necrosis had worse outcome. The aggressive behavior of advanced OSCC could be partially related to PD-L1 immune escape. These patients may be good candidates for anti-PD-L1 immunotherapy.

Keywords
Advanced stage Disease-free survivals HIF-1α Magnetic resonance imaging Metastatic lymph nodes Oral cancer Overall survival PD-L1 immune escape Squamous cell carcinoma Tumor necrosis
MeSH Terms
Adult Aged Aged, 80 and over B7-H1 Antigen/metabolism Carcinoma, Squamous Cell/metabolism,pathology Female Humans Hypoxia-Inducible Factor 1, alpha Subunit/metabolism Lymph Nodes/pathology Lymphatic Metastasis/pathology Magnetic Resonance Imaging Male Middle Aged Mouth Neoplasms/metabolism,pathology Neck Necrosis Prognosis Retrospective Studies
Chemicals
B7-H1 Antigen CD274 protein, human Hypoxia-Inducible Factor 1, alpha Subunit
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Chen Tseng-Cheng
Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan; Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10002, Taiwan.
Wu Chen-Tu
Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan; Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10002, Taiwan.
Wang Cheng-Ping
Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan; Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10002, Taiwan.
Hsu Wan-Lun
Genomics Research Center, Academia Sinica, Taipei, Taiwan.
Yang Tsung-Lin
Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan.
Lou Pei-Jen
Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan.
Ko Jenq-Yuh
Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan.
Chang Yih-Leong
Department of Pathology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 10002, Taiwan; Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10002, Taiwan. Electronic address: ntuhylc@gmail.com.
Article Info
Journal
Oral oncology
Abbr.
Oral Oncol
ISSN
1879-0593
Published
2015-11-00
Epub
2015-00-11
Pages
1004-1010
Language
English
Region
England
NLM ID
9709118
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com